By staff writers

August 6, 2010 -- Raman molecular imaging (RMI) shows promise in identifying cancers that are typically difficult to diagnose, according to a study scheduled for presentation this week at the International Conference on Raman Spectroscopy (ICORS) in Boston.

RMI combines image information with spectral data in each pixel to imprint a digital molecular stain, unique to each sample, without the use of reagents. Images are acquired from tissue samples illuminated by a laser in a microscope and then analyzed by chemometric-based classification algorithms.

According to the study, RMI has shown promise in differentiating disease states in tissue, especially in the kidney and prostate.

ChemImage of Pittsburgh currently is conducting and presenting research on how RMI can discriminate between two challenging kidney disease diagnoses -- oncocytoma, a benign condition, and chromophobe renal cell carcinoma, a malignant one -- and predict progression in prostate cancer, where slow-growing prostate cancer is difficult to differentiate from more aggressive forms.

Stanford researchers on path to novel molecular imaging technique, April 10, 2008

Raman spec reveals bone strength, October 28, 2005

Copyright © 2010


To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking